Phase 2 trial of Oxford Covid-19 vaccine candidate begins in Pune


Pune, August 26

The Phase 2 scientific trial of the Oxford COVID-19 vaccine, being manufactured by the city-based Serum Institute of India (SII), started at a medical faculty and hospital right here on Wednesday.

Two male volunteers have been administered the vaccine at Bharti Vidyapeeth’s Medical College and Hospital, a senior office-bearer of the hospital mentioned.

The trial started round 1 pm, he mentioned.

“Doctors at the hospital administered the first shot of the ‘Covishield’ vaccine to a 32-year-old man after his reports of COVID-19 and antibodies tests came out negative,” Medical Director of Bharti Vidyapeeth’s Medical College, Hospital and Research Centre, Dr Sanjay Lalwani, mentioned.

Another 48-year-old male volunteer was additionally given the vaccine, he added.

While the 32 year-old volunteer works for a non-public firm, the opposite one is related to the healthcare sector, he mentioned.

“Before administering the vaccine, doctors checked their temperature, blood pressure and heart beats,” he mentioned.

Five volunteers had enrolled themselves for the trial after the doses have been acquired from the SII on Tuesday, he added.

“The COVID-19 and antibodies tests were conducted on all the five volunteers. Of them, the reports of three volunteers’ antibodies test came out positive. So they became ineligible for the trial,” Dr Lalwani mentioned.

“The two other volunteers, who were administered the vaccines are being monitored,” he mentioned.

According to Dr Lalwani, in all 25 candidates will given the vaccine within the subsequent seven days.

SII, the world’s largest vaccine maker, has signed an settlement to fabricate the potential vaccine developed by the Jenner Institute of Oxford University in collaboration with British-Swedish pharma firm AstraZeneca. PTI



Be the first to comment on "Phase 2 trial of Oxford Covid-19 vaccine candidate begins in Pune"

Leave a comment

Your email address will not be published.


*


%d bloggers like this: